089sek
15,9 %
Date:2025-05-14Time:18:00:00Latest report:Q3-2025List:First NorthTicker:BIOVIC B
Market Cap:87 msekEnterprise Value:50 msekNet Sales:8,19 msekEarnings:-106,4 msekEmployees:0ISIN:SE0008613731

Ratios

10-year key figure history for Biovica turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Biovica with index and moving average MA50 and MA200.

Stockprice:0,89
MA50:1,01
MA200:1,95
Price/MA200:-54,5 %
RSI (14):55,4
Price/MA50:-12,0 %

Description

Biovica International is a pharmaceutical company that focuses its research on cancer treatments. The company is developing methods for measuring cell proliferation, where the test is taken via blood samples. The tests analyze the risk for the development of the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main area of focus is within treatment of breast cancer. The company was founded in 2008 and is headquartered in Uppsala.

Biotechnology